risks with glp 1 GLP-1 Medications Infographic Frontiers | Exploring the multifaceted
Description
doi:10.1038/nrgastro.2015.150
Fiber can also promote intestinal health
Lilly intends to submit the drug to regulators by the end of 2025, positioning it as the first oral GLP-1 receptor agonist approved specifically for obesity
Acute cholecystitis associated with the use of glucagon-like peptide-1 receptor agonists reported to the US Food and Drug Administration
This discovery led to further investigations into its potential as a weight loss medication
PMID: 54 HayashiT.SuT
